Your dedicated biometrics partner for measurable outcomes
Complex clinical trials need more than biometrics delivery. They need judgement,
knowing which endpoints will stand up, where data issues may emerge and what
regulators will expect. We bring that thinking across the full biometrics
workflow, so teams can act earlier and move forward with confidence.
Our work starts with the data and the expertise behind it. Focus and precision guide every step, building biometrics you can trust and evidence that leads to better-informed decisions.
Data
Every study begins with data points that build the evidence needed to answer the key clinical and statistical questions.
Focus
Our experts bring direction to that data, concentrating on the endpoints, trends and sources of variability that shape the study.
Precision
With that focus set, we apply the right statistical methods and quality controls so the analysis is robust, reproducible and aligned with the protocol.
Excellence
The result reflects the standard we work towards every day: delivery that meets the scientific, operational and regulatory demands of the study.
Trusted expertise that delivers
Specialised biometrics support for complex clinical trials, bringing together senior
expertise, agile technology and regulatory-ready delivery for mid-sized biotech
and pharma.
Biostatistical Services
Biostatisticians deliver end-to-end support, from study design and SAP development to statistical reporting and submissions.
Sometimes the hardest part is knowing where to begin. Our senior consultants
help you clarify priorities, weigh development challenges, and find the right
path forward across study design, statistics, regulatory strategy and data.
We deliver flexible, data-driven solutions that bring clarity and confidence to complex clinical trials.
36years of experience
800+studies
160+employees
95%staff retention
5locations
150+global customers
What sets our partnership apart
Proven expertise
36 years of biometrics experience gives sponsors proven expertise, reliable delivery and confidence in regulatory-ready results.
Privately owned
Metronomia has been privately held and has grown organically since 1990. With no financial investor and no corporate group behind us, we can take a long-term view of our teams, technology and client partnerships.
Direct access to senior experts
Senior specialists stay actively involved from study set-up through delivery, giving you direct access to experienced judgement and consistent oversight at every stage.
Flexible when the study changes
Clinical programmes rarely stay exactly as planned. We adapt quickly when priorities, timelines or study needs shift, bringing the experience to adjust without losing control of the wider programme.
A proactive partner you can trust
We don’t just execute; we anticipate challenges and provide strategic recommendations. You gain a partner who actively helps de-risk your program, strengthens trial designs, and ensures faster, smarter outcomes.
Continuity built into the team
With 95% staff retention and right-sized teams, we keep the people and knowledge around your study consistent, reducing handovers and bringing greater stability throughout delivery.
Our people are at the core of everything we do, connecting your data to quality
outcomes you can trust. With deep expertise across biometrics and a shared
commitment to excellence, we foster a culture built on trust, collaboration,
and long-term partnerships.
Volume II – Process Debt: The Hidden Cost of Scaling Without Process Redesign
20 May 2026Whitepaper
As CDM organisations scale, hidden operational pressures accumulate beneath successful delivery — until they affect quality, timelines and workforce sustainability. Volume II reveals the risks of scaling without process redesign.
Volume I – Sustainable Scale: Designing People-Centric Operating Models for Complex Trials
15 April 2026Whitepaper
As Clinical Data Management grows more complex, many organisations are asked to scale faster than their operating models allow. Volume I explores people-centric operating models built for complexity, accountability and resilience.
As AI transforms medical writing, teams must adopt new tools without sacrificing scientific accuracy or regulatory compliance. This paper weighs innovation against ethical responsibility and the need for expert human oversight.
